Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Daniel Podzamczer

Showing results (171-180 of 181) with videos related to

Pageof 19
Sort By:
The Lancet. Infectious Diseases|February 15, 2014
Safety and efficacy of the peptide-based therapeutic vaccine for HIV-1, Vacc-4x: a phase 2 randomised, double-blind, placebo-controlled trialRichard B Pollard, Jürgen K Rockstroh, Giuseppe Pantaleo, et al.
Enfermedades Infecciosas Y Microbiologia Clinica|February 26, 2017
Executive summary: Pre-exposure prophylaxis for prevention of HIV infection in adults in Spain: July 2016Santiago Moreno, Antonio Antela, Felipe García, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|November 16, 2011
Calendar time trends in the incidence and prevalence of triple-class virologic failure in antiretroviral drug-experienced people with HIV in Europe, , Fumiyo Nakagawa, et al.
The Journal of Infectious Diseases|December 11, 2012
Predictors of CD4(+) T-cell counts of HIV type 1-infected persons after virologic failure of all 3 original antiretroviral drug classes, Dominique Costagliola, Bruno Ledergerber, et al.
Enfermedades Infecciosas Y Microbiologia Clinica|July 3, 2014
Executive summary of the GeSIDA/National AIDS Plan consensus document on antiretroviral therapy in adults infected by the human immunodeficiency virus (updated January 2014), Juan Berenguer, Rosa Polo, et al.
Enfermedades Infecciosas Y Microbiologia Clinica|May 30, 2015
Executive summary of the GESIDA/National AIDS Plan Consensus Document on antiretroviral therapy in adults infected by the human immunodeficiency virus (updated January 2015), Juan Berenguer, Rosa Polo, et al.
Medicine|February 13, 2016
The F4/AS01B HIV-1 Vaccine Candidate Is Safe and Immunogenic, But Does Not Show Viral Efficacy in Antiretroviral Therapy-Naive, HIV-1-Infected Adults: A Randomized Controlled TrialWarren Dinges, Pierre-Marie Girard, Daniel Podzamczer, et al.
Archives of Internal Medicine|March 10, 2010
Triple-class virologic failure in HIV-infected patients undergoing antiretroviral therapy for up to 10 years, Rebecca Lodwick, Dominique Costagliola, et al.
Enfermedades Infecciosas Y Microbiologia Clinica|April 9, 2016
Executive summary: Prevention and treatment of opportunistic infections and other coinfections in HIV-infected patients: May 2015José Antonio Iribarren, Rafael Rubio, Koldo Aguirrebengoa, et al.
Enfermedades Infecciosas Y Microbiologia Clinica|March 16, 2016
Prevention and treatment of opportunistic infections and other coinfections in HIV-infected patients: May 2015José Antonio Iribarren, Rafael Rubio, Koldo Aguirrebengoa, et al.
Pageof 19

Showing results (171-180 of 181) with videos related to

Sort By:
Pageof 19
The Lancet. Infectious Diseases|February 15, 2014
Safety and efficacy of the peptide-based therapeutic vaccine for HIV-1, Vacc-4x: a phase 2 randomised, double-blind, placebo-controlled trialRichard B Pollard, Jürgen K Rockstroh, Giuseppe Pantaleo, et al.
Enfermedades Infecciosas Y Microbiologia Clinica|February 26, 2017
Executive summary: Pre-exposure prophylaxis for prevention of HIV infection in adults in Spain: July 2016Santiago Moreno, Antonio Antela, Felipe García, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|November 16, 2011
Calendar time trends in the incidence and prevalence of triple-class virologic failure in antiretroviral drug-experienced people with HIV in Europe, , Fumiyo Nakagawa, et al.
The Journal of Infectious Diseases|December 11, 2012
Predictors of CD4(+) T-cell counts of HIV type 1-infected persons after virologic failure of all 3 original antiretroviral drug classes, Dominique Costagliola, Bruno Ledergerber, et al.
Enfermedades Infecciosas Y Microbiologia Clinica|July 3, 2014
Executive summary of the GeSIDA/National AIDS Plan consensus document on antiretroviral therapy in adults infected by the human immunodeficiency virus (updated January 2014), Juan Berenguer, Rosa Polo, et al.
Enfermedades Infecciosas Y Microbiologia Clinica|May 30, 2015
Executive summary of the GESIDA/National AIDS Plan Consensus Document on antiretroviral therapy in adults infected by the human immunodeficiency virus (updated January 2015), Juan Berenguer, Rosa Polo, et al.
Medicine|February 13, 2016
The F4/AS01B HIV-1 Vaccine Candidate Is Safe and Immunogenic, But Does Not Show Viral Efficacy in Antiretroviral Therapy-Naive, HIV-1-Infected Adults: A Randomized Controlled TrialWarren Dinges, Pierre-Marie Girard, Daniel Podzamczer, et al.
Archives of Internal Medicine|March 10, 2010
Triple-class virologic failure in HIV-infected patients undergoing antiretroviral therapy for up to 10 years, Rebecca Lodwick, Dominique Costagliola, et al.
Enfermedades Infecciosas Y Microbiologia Clinica|April 9, 2016
Executive summary: Prevention and treatment of opportunistic infections and other coinfections in HIV-infected patients: May 2015José Antonio Iribarren, Rafael Rubio, Koldo Aguirrebengoa, et al.
Enfermedades Infecciosas Y Microbiologia Clinica|March 16, 2016
Prevention and treatment of opportunistic infections and other coinfections in HIV-infected patients: May 2015José Antonio Iribarren, Rafael Rubio, Koldo Aguirrebengoa, et al.
Pageof 19